W
WAVEMAN · COMPANY
IVVD · Invivyd, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

IVVD

Invivyd, Inc.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001832038
FORM 144 · 5☆ WATCH
INSIDER NET · 180D
-$177.1K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
73
13F, latest reported quarter
REVENUE GROWTH
+110.5%
XBRL, annual
NET MARGIN
-98.2%
CONVERSIONS · 180D
5
codes C/M, not in net · no price filed
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$177.1K over 180 days
-$177.1K over 90 days
more than 52% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
73 funds added or opened last quarter
more than 54% of Pharma & Biotech
REVENUE
+110.5% year over year
more than 86% of Pharma & Biotech
MARGIN
-98.2% net margin
below 65% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
9.4% of shares outstanding short · 8.9 days to cover · settled 2026-07-31
more than 74% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$177.1K across 5 people in 180 days.
73 funds added or opened positions in the latest 13F quarter, of 127 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -19.8%
-19.8%12M
-48%+28%+104%+180%2025-092025-102025-122026-032026-052026-072026-09 2025-11-19 · MCLAUGHLIN KEVIN F bought $125.0K2026-02-18 · Andersen Jill sold $55.2K2026-02-17 · Andersen Jill sold $50.5K2026-02-18 · Green Julie sold $33.1K2026-02-18 · Duke William E. sold $33.1K2026-02-18 · Lee Timothy Edward sold $33.1K2026-02-18 · Allen Robert D. III sold $30.6K2026-02-17 · Green Julie sold $30.3K2026-02-17 · Duke William E. sold $30.3K2026-02-17 · Lee Timothy Edward sold $30.3K2026-02-17 · Allen Robert D. III sold $28.0K2026-08-17 · Andersen Jill sold $26.9K2026-08-18 · Andersen Jill sold $25.9K2026-08-17 · Lee Timothy Edward sold $16.1K2026-08-17 · Green Julie sold $16.1K2026-08-17 · Duke William E. sold $16.1K2026-08-18 · Lee Timothy Edward sold $15.5K2026-08-18 · Green Julie sold $15.5K2026-08-18 · Duke William E. sold $15.5K2026-08-17 · Allen Robert D. III sold $14.9K2026-08-18 · Allen Robert D. III sold $14.4K2026-08-17 · Allen Robert D. III filed to sell $27.2K2026-08-17 · Andersen Jill filed to sell $49.0K2026-08-17 · Duke William E. filed to sell $29.4K2026-08-17 · Green Julie filed to sell $29.4K2026-08-17 · Lee Timothy Edward filed to sell $29.4K
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $177.1K sold by insiders over 180 days, 73 funds added last quarter, $164.5K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Invivyd, Inc. insiders sold a net $177.1K of stock across 48 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Lee Timothy Edward
Chief Commercial Officer
SELL
2026-08-18
18,425.0
$15.5K
Green Julie
Chief Human Resources Officer
SELL
2026-08-18
18,425.0
$15.5K
Duke William E.
Chief Financial Officer
SELL
2026-08-18
18,425.0
$15.5K
Andersen Jill
Chief Legal Officer, Secretary
SELL
2026-08-18
30,706.0
$25.9K
Allen Robert D. III
Chief Scientific Officer
SELL
2026-08-18
17,043.0
$14.4K
48 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 43 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Jupiter Topco LLC
34,173,104.0 sh
$30.0M
BVF INC/IL
28,165,000.0 sh
$24.6M
MAVERICK CAPITAL LTD
18,970,913.0 sh
$16.6M
PERCEPTIVE ADVISORS LLC
18,490,636.0 sh
$16.1M
BlackRock, Inc.
16,134,885.0 sh
$14.1M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Allen Robert D. III
FILED 2026-08-17
$27.2K
Andersen Jill
FILED 2026-08-17
$49.0K
Duke William E.
FILED 2026-08-17
$29.4K
Green Julie
FILED 2026-08-17
$29.4K
Lee Timothy Edward
FILED 2026-08-17
$29.4K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Eventide Healthcare & Life Sciences Fund
$11.8M POSITION · AS OF 2026-03-31
0.7%
Virtus Biotech Clinical Trials Etf
$166.6K POSITION · AS OF 2026-04-30
0.4%
Driehaus Micro Cap Growth Fund
$730.6K POSITION · AS OF 2026-03-31
0.2%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$7.4M POSITION · AS OF 2026-03-31
0.1%
Ultra-Small Company Market Fund
$121.4K POSITION · AS OF 2026-03-31
0.1%
PROFUND VP BIOTECHNOLOGY
$40.9K POSITION · AS OF 2026-03-31
0.1%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 8 registered trials, 3 still enrolling or running — a status change here is dated weeks before the press release
2
Phase 1
1 ACTIVE
3
Phase 3
2 ACTIVE
1
Not applicable
0 ACTIVE
2
Multi-phase
0 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$53.4M$25.4M$0—
OPERATING INCOME$-55.6M$-176.9M$-212.8M$-248.0M
NET INCOME$-52.5M$-169.9M$-198.6M$-241.3M
EPS (DILUTED)-0.30-1.43-1.81-2.23
OPERATING CASH FLOW$-58.1M$-170.5M$-173.2M$-220.0M
CASH$226.7M$69.3M$200.6M$92.1M
BUYBACKS—$0$1.0K$4.0K
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →